{"id":"W2944461353","doi":"10.1158/1538-7445.sabcs18-p6-18-14","title":"Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Goserelin; Fulvestrant; Anastrozole; Breast cancer; Clinical endpoint; Oncology; Cancer; Placebo; Aromatase inhibitor; Metastatic breast cancer; Progression-free survival; Palbociclib; Clinical trial; Chemotherapy; Estrogen receptor; Aromatase; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00190768,0.0005291979,0.001394965,0.0002809875,0.0002543316,0.00008530543,0.0003413646,0.0001970854,0.001070652],"category_scores_gemma":[0.000489803,0.0003208496,0.0001622203,0.001002661,0.0007345781,0.0003814069,0.00008836481,0.001266211,0.00001865736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000974378,"about_ca_system_score_gemma":0.001360949,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02161763,"about_ca_topic_score_gemma":0.001757647,"domain_scores_codex":[0.9944504,0.0006841911,0.001140062,0.001175875,0.001577874,0.0009716213],"domain_scores_gemma":[0.9932411,0.003740838,0.0006479367,0.0009790645,0.001052352,0.0003386804],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2621681,0.001274693,0.08105882,0.00006677047,0.00157329,0.0001575705,0.00602162,0.0006228414,0.1759817,0.00001454323,0.001053026,0.470007],"study_design_scores_gemma":[0.1436317,0.002459232,0.7905594,0.001783879,0.00009035809,0.00001745569,0.003186257,0.00008060812,0.05187332,0.0002283421,0.005405918,0.0006836217],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9755027,0.005920408,0.00001495771,0.01033643,0.0001928891,0.004416529,0.003234569,0.00008062898,0.0003009452],"genre_scores_gemma":[0.9929104,0.003603368,0.000338062,0.0007610497,0.0002452615,0.0013225,0.0002286678,0.0001167997,0.0004738533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7095006,"threshold_uncertainty_score":0.9999244,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07544344919931267,"score_gpt":0.4165428332646931,"score_spread":0.3410993840653804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}